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Abstract: Warfarin (3-(α-acetonylbenzyl)-4-hydroxy coumarin) is a vitamin K 
(VK) antagonist that inhibits vitamin K-dependent (VKD) processes, such as 
blood coagulation. It also exerts an influence on some non-VKD-related 
activities. In this study, the effect of sub-acute (30-day) oral warfarin (2 and 1 
mg L-1) intake on hematological parameters was examined in two rat strains, 
Albino Oxford (AO) and Dark Agouti (DA), that differ in their sensitivity to 
certain chemicals. Greater susceptibility to the anticoagulant effect of 2 mg L-1 
of warfarin was observed in AO rats and was associated with an increase in the 
relevant hematological parameters in this strain. Although both strains 
responded to 2 mg L-1 of warfarin with quantitative changes in the peripheral 
blood leukocytes, differential bone marrow and lung responses were observed. 
Strain-related differences in the pro-inflammatory activity of peripheral blood 
granulocytes and in mononuclear cell IFN-γ production were observed. 
Recognition of differences in quantitative and qualitative effects of oral 
warfarin on processes other than hemostasis might be of relevance for those 
humans who are on warfarin therapy.  
Keywords: warfarin; rats; anticoagulant effect; hematology; peripheral blood 
leukocytes. 
INTRODUCTION 
Warfarin (3-(α-acetonylbenzyl)-4-hydroxy coumarin) and other coumarin 
analogs are antagonists of vitamin K that inhibit the vitamin K-dependent (VKD) 
step in the synthesis of several factors required for normal blood coagulation.1 
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Interference with the synthesis of biologically active coagulation factors results 
in increases in the clotting time up to the point where no clotting occurs. Anti-
coagulants of the 4-hydroxy-coumarin type are used in prophylactic medicine to 
prevent thromboembolic diseases and as pesticides for rodents (anticoagulant 
rodenticides).2,3 Warfarin inhibits vitamin K epoxide reductase (VKOR), giving 
rise to depletion of hydroquinone, a co-factor for the γ-glutamyl carboxylase, an 
enzyme that mediates carboxylation of glutamyl (Gla) residues on precursors of 
several proteins involved in coagulation, including II (FII, prothrombin), VII 
(FVII), IX (FIX), and X (FX) factors.2 Inhibition of VKOR by warfarin also 
affects the catalytic rate of other VKD proteins, such as proteins required for the 
regulation of bone growth and calcification (bone Gla protein, BGP/osteocalcin 
and matrix Gla protein, MGP) as well as those involved in the growth of vascular 
smooth muscle cells and mesangial cells.4–7 Moreover, warfarin exerts influence 
on some non-VKD-related activities, including anti-tumor and 
immunomodulating activities.8,9 As regards the immune system, both stimulatory 
and suppressive effects of warfarin (and other coumarin congeners) were 
observed.10–15 Some clinical complications of warfarin therapy and adverse 
reactions associated with inflammatory cells attendance in affected tissues 
implies the pro-inflammatory potential of this chemical.16–21 
It was previously demonstrated that acute (intraperitoneal or epicutaneous 
route) or sub-acute oral administration of warfarin at doses resulting in antico-
agulation exert systemic pro-inflammatory effects in rats and suggested that peri-
pheral blood neutrophils are the target of this agent.22–25 The impact of sub-acute 
oral warfarin intake on other hematological parameters besides peripheral blood 
leukocyte numbers and mononuclear cell activity was explored in this study in 
order to see whether there were broader effects of warfarin at the systemic level. 
Bearing in mind the well-known differences in the response of humans to antico-
agulation by warfarin,26 these effects were examined comparatively in two rat 
strains known for their differences in immune responses to chemical insult, i.e., 
Albino Oxford (AO) and Dark Agouti (DA) rats.27,28 
EXPERIMENTAL 
Chemicals 
Warfarin sodium (Serva Feinbiochemica, Heidelberg, Germany), dextran 500,000, 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), phorbol-12-myristate- 
-13-acetate (PMA), hexadecyltrimethylammonium bromide (HTAB), o-dianisidine dihydro-
chloride and myeloperoxidase (MPO) (all from Sigma Chemical Co., St. Louis, MO, USA), 
nitroblue tetrazolium (NBT) (ICN Pharmaceutical, Costa Mesa, CA, USA), concanavalin-A 
(ConA) (Pharmacia, Uppsala, Sweden) were used in experiments. The culture medium RPMI-
1640 (PAA laboratories, Austria) supplemented with 2 mM glutamine, 20 μg mL-1 genta-
mycin (Galenika a.d., Serbia) and 5 % (v/v) heat-deactivated fetal calf serum (PAA Labo-
ratories, Austria), i.e., complete medium, was used in the cell culture experiments. 
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Animals and warfarin treatment 
Twelve-week old, female DA (weighing 200–232 g) and AO rats (weighing 295–325 g), 
conventionally housed at the Institute for Biological Research “Siniša Stanković” (Belgrade, 
Serbia) were used in the experiments. The treatments were performed in adherence with the 
Guidelines of the Ethical Committee of the Institute. In the pilot experiments, rats were given 
4 mg L-1 of warfarin solution in drinking water, which (at consumption volume of 20–30 mL 
of solution daily) corresponded to 0.367 (±0.047) mg of warfarin per kg daily. However, mas-
sive hemorrhage was observed in AO rats during the last week of warfarin intake, with 
subsequent death of more than 80 % of individuals, while less than 15 % of the DA rats died. 
No fatal outcome was observed in either rat strain at two (2 mg L-1) and four times (1 mg L-1) 
lower warfarin doses. Thus, the consequences of the intake of these two lower non-lethal 
warfarin doses were analyzed further. At least two independent experiments were conducted 
with four to six animals assigned to each treatment group. Rats were given warfarin solution 
in drinking water ad libitum for 30 days. Control rats were given drinking water only.  
Prothrombin time 
The prothrombin time (PT) was determined in samples of blood withdrawn from the 
abdominal artery diluted in citrate buffer (blood to citrate ratio 5:1) by a one-stage method 
using citrate plasma and Thromborel S reagents (Behring Diagnostics GmbH, Marburg, 
Germany) with Siemens BCS-XP Dade Behring equipment (Marburg, Germany).  
Hematology  
Complete blood tests analyses were conducted automatically using a Siemens ADVIA 
120 flow cytometer (Terytown, N.Y., USA). In this way, the white blood cell count (WBC) 
and percentage of leukocytes, red blood cell count (RBC), hemoglobin concentration (Hb), 
hematocrit (HCT), mean corpuscle volume (MCV), platelet number (PLT) and mean platelet 
volume (MPV) were measured. 
Bone marrow leukocyte counts  
Total bone marrow counts were determined using an improved Neubauer hemocytometer 
following cell staining with Türck solution. Differential cell counts were determined by 
differentiating at least 1000 cells of bone marrow smears stained according to the May–
Grünwald–Giemsa protocol.  
Lung histology  
Lungs were excised, cut and immediately fixed in 4 % formaldehyde (pH 6.9). After 
processing, the tissue was embedded in paraffin wax for sectioning at 5 μm. Hematoxylin and 
eosin (H&E)-stained histology slides were subsequently analyzed in a blinded manner by 
experienced pathologist using a Coolscope digital light microscope (Nikon Co., Tokyo, 
Japan). 
Peripheral blood granulocyte and mononuclear cell isolation  
Peripheral blood leukocytes were isolated from the heparinized blood by dextran sedi-
mentation and centrifugation (700 g, 20 min at room temperature) on an OptiPrep (Nycomed 
AS, Norway) density gradient. Polymorphonuclear cells (granulocytes) were obtained from 
the pellet fraction, following the lysis of erythrocytes with the isotonic NH4Cl solution. The 
mononuclear cells were harvested from the band at the interface of plasma and OptiPrep 
density medium. 
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MTT assay for leukocyte viability 
Granulocyte and mononuclear viability was determined in freshly isolated cells by a 
quantitative colorimetric assay for metabolic viability described for humans,29 which is based 
on the reduction of the tetrazolium salt MTT to a colored end-product, formazan, by several 
mitochondrial dehydrogenases in viable cells. The formazan produced was dissolved in an 
acidified sodium dodecyl sulfate solution (10 % SDS–0.01 M HCl) and the optical density 
(OD) was measured using a microplate spectrophotometer (GRD, Rome, Italy) at 540 nm.  
Peripheral blood granulocyte and mononuclear cell activity 
Granulocyte activation was evaluated by a cytochemical nitroblue tetrazolium (NBT) 
reduction assay for the respiratory burst based on the capacity of granulocytes to reduce NBT 
via respiratory burst oxidase.30 Briefly, NBT (10 μL, 5 mg mL-1) was added to a granulocyte 
suspension (5×105 cells well-1 of a 96-well plate, in 100 μL) and incubated for 30 min with 
100 ng mL-1 PMA (stimulated NBT reduction) or solely in medium (spontaneous NBT 
reduction). The absorbance of the produced formazan was measured as described above.  
The granulocyte myeloperoxidase (MPO) activity was assessed based on the oxidation of 
o-dianisidine dihydrochloride by cells.31 To 966 μL of substrate solution (0.167 mg mL-1 o-
dianisidine dihydrochloride and 0.0005 % H2O2 in 50 mM potassium phosphate buffer, pH 
6.0), 33 μL of granulocyte lysate, obtained by repeated freeze–thaw, was added. The absor-
bance was read at 450 nm (at three-minute intervals up to ten minutes) against an MPO 
standard. The values are expressed as MPO units per 106 cells.  
To examine interferon-γ (IFN-γ) production, mononuclear cells were cultured at 5×105 
cells well-1 in a 96-well plate for 48 h in culture medium solely (spontaneous production) or in 
the presence of 1 μg mL-1 of ConA (ConA-stimulated production). The concentration of IFN-γ 
produced was measured by enzyme-linked immunosorbent assays (ELISA) for rat IFN-γ 
(R&D systems, Minneapolis, USA). The cytokine titer was calculated using a standard curve 
constructed with known amounts of recombinant IFN-γ. 
Data display and statistical analysis 
The results were obtained from two independent experiments and are expressed as means 
± standard deviation (SD). Statistical analysis was performed using Statistica 6.0 (StatSoft 
Inc., Tulsa, Oklahoma, USA). The statistical significance was defined by the Mann–Whitney 
U test. Values of p less than 0.05 were considered significant. 
RESULTS 
Anticoagulant effects of warfarin  
Rats were given 1 and 2 mg L–1 of warfarin in their drink water. Every indi-
vidual consumed 20–30 mL of warfarin solution daily, in this way consuming 
0.090±0.009 (0.078–0.107) and 0.191±0.016 (0.164–0.215) mg kg–1 day–1 at 1 
and 2 mg L–1, respectively. Prolongation of the mean prothrombin time was 
observed in the AO rats following consumption of 2 mg L–1 of warfarin only 
(Fig. 1). No changes in PT were observed at the lower (1 mg L–1) warfarin dose.  
Hematology 
Thirty-day consumption of 2 mg L–1 of warfarin resulted in significantly 
lower total leukocyte counts and in a tendency (p = 0.07) of decreasing in the AO 
and DA rats, respectively (Table I). A decrease in lymphocyte with unchanged 
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neutrophil concentrations was observed in the individuals of both strains. Besides 
leukocytes, several other hematological parameters were affected in AO rats, in-
cluding an increase in red blood cell counts, hemoglobin concentration, hema-
tocrit, mean corpuscle volume and platelet counts. No changes in these parame-
ters were observed in DA rats, although the highly variable platelet counts re-
sulted in a numerical increase at this warfarin dose. Consumption of 1 mg L–1 
was without effect, except for an increase in HCT in AO rats. 
 
Fig. 1. Anticoagulant effect of warfarin intake in AO and DA rats expressed through the 
prothrombin time (PT). The results are expressed as mean values ± SD from two independent 
experiments with six animals per each animal group. Significance at * p < 0.05 vs. controls 
(0 mg L-1 of warfarin) of the respective strain. 
Bone marrow leukocyte counts 
Given the quantitative changes in the peripheral blood leukocytes at 2 mg L–1 
of warfarin, an analysis of bone marrow leukocytes was conducted in rats that 
consumed this warfarin dose. Significant increase in number of immature neu-
trophils (metamyelocytes) and a tendency (p = 0.060) of an increase in the ma-
ture granulocyte pool were observed only in DA rats (Table II). No changes in 
the number of lymphocytes or monocytes were observed in either strain. 
Lung histology 
As lungs harbor an intravascular reservoir of leukocytes, predominantly 
neutrophils, called marginated pool, which constantly exchanges with the circul-
ating cells,31 histological analysis of lungs from rats that consumed 2 mg L–1 of 
warfarin was conducted next (Fig. 2). It revealed neutrophil attendance in AO 
rats (neutrophil lung infiltration noted in three out of four animals), as compared 
to DA rats, where neutrophils were observed in the lungs of one out of four 
individuals that had consumed warfarin. 
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TABLE II. Total and differential bone marrow leukocyte counts; data represent the mean 
values ±SD from two independent experiments with four to six animals per group 
Cell number 
× 10-6 per femur 
DA 
Warfarin dose, mg L–1 
AO 
Warfarin dose, mg L–1 
Parameter 0 2 0 2 
Total 72.4±10.7 74.9±6.6 72.7±7.1 70.7±1.2 
Metamyelocyte 8.70±2.1 11.77±2.3a 6.48±0.9 6.36±0.4 
Granulocyte 31.02±4.9 34.16±3.2 24.92±3.5 24.21±0.8 
Lymphocyte 31.73±5.7 29.82±9.0 40.42±4.1 39.19±1.5 
Monocyte 0.94±0.3 1.13±0.5 0.83±0.2 0.88±0.1 
aSignificantly different from control animals of the respective strain (0 mg L-1) at p < 0.05 
 
Fig. 2. Histology of lungs of an AO rat following oral intake of 2 mg L-1 of warfarin. 
Perivascular neutrophil attendance and interstitial edema. Inset: lung histology 
of a control animal (0 mg L-1 of warfarin). 
Peripheral blood granulocyte viability and activity  
To determine whether there were qualitative changes in the peripheral blood 
leukocytes, some of the basic aspects of activity (metabolically-based viability, 
activation/priming for respiratory burst and myeloperoxidase activity) were exa-
mined in neutrophils taken from animals that had consumed the higher warfarin 
dose (2 mg L–1). As shown in Fig. 3, an increase in the MTT reduction by freshly 
isolated peripheral blood granulocytes of DA rats that had consumed warfarin 
was observed, while a similar capacity of reduction was observed in the control 
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and warfarin-exposed AO rats (Fig. 3A). No difference in level of spontaneous 
NBT reduction could be observed between the control and rats that had con-
sumed warfarin (Fig. 3B). Stimulation with PMA resulted in an increase in the 
NBT reduction by cells from the control and treated animals of both strains. 
Although PMA-stimulated NBT reduction capacity was more pronounced in AO 
compared to DA rats (p < 0.05), no difference was noted between control and the 
warfarin-treated AO rats, while the levels of reduction attained in DA rats that 
had consumed warfarin were higher than those from the controls.  
Measurements of the intracellular MPO content in neutrophils revealed lower 
values in the control DA (vs. AO) rats, but it increased significantly after warfarin 
consumption in the DA rats (Fig. 3C), while it remained unchanged in the AO rats. 
Peripheral blood mononuclear cell viability and activity  
As a drop in the peripheral blood lymphocyte counts was observed in rats that 
had consumed 2 mg L–1 of warfarin, the viability of the blood mononuclear cells 
was next determined. No difference in MTT reduction was observed between the 
control and the warfarin-treated rats of either strain (Fig. 4A). To determine whether 
warfarin exerted an influence on the mononuclear cell activity, the production of 
IFN-γ was determined (Fig. 4B). While there was no effect on the spontaneous 
IFN-γ production by mononuclear cells from DA rats, consumption of warfarin 
resulted in an increase in the AO rats. Stimulation with ConA, however, resulted 
in significantly higher production of this cytokine in DA rats that had consumed 
warfarin, while it was similar in the control and warfarin-treated AO rats.  
DISCUSSION 
In this study, the effects of sub-acute (30-day) oral intake of warfarin on 
hematological parameters and on peripheral blood granulocyte and mononuclear 
cell activity were examined comparatively in two rat strains known to differ in 
their susceptibility to chemical insult. The lower susceptibility to the anticoagu-
lant effect of warfarin, the increase in some of the hematological parameters 
(RBC and PLT counts, Hb concentration and HCT values) as well as the lack of 
qualitative effects (peripheral blood granulocyte) or different pattern of mono-
nuclear cell activity in DA vs. AO rats demonstrated the differential responsive-
ness to warfarin treatment in the two rat strains. The differential susceptibility to 
hemorrhage might have accounted for differences in mortality at the highest 
warfarin dose, in line with data showing that impaired coagulation, along with 
the hemorrhage generally resulted in the death of rodents.3 The increase in pro-
thrombin time, which reflects the basic biological activity of warfarin, at a dose 
that resulted in no changes in this parameter in DA rats, also depicts the higher 
responsiveness of AO rats to warfarin anticoagulation. Strain-related differences 
in the metabolism of warfarin shown in laboratory rat strains32,33 might be res-
ponsible for the differences observed in the prothrombin time in AO vs. DA rats. 
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Differences in cytochrome P450 (CYP) enzymes as well as vitamin K epoxide 
reductase complex subunit 1 (VKORC1) might have accounted for these diffe-
rences, as polymorphism in these enzymes affects the anticoagulant action of 
warfarin in humans.34 
 
 
 
Fig. 3. The effect of warfarin intake on peripheral blood granulocyte viability and activity. A. 
Reduction of MTT. B. The spontaneous and PMA-stimulated reduction of NBT. C. 
Intracellular MPO activity. The results are expressed as mean values ± SD from two 
independent experiments with four to six animals per group. Significance at * p < 0.05 vs. 
controls (0 mg L-1 of warfarin) of the respective strain. 
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Fig. 4. The effect of warfarin intake on peripheral blood mononuclear cell viability and 
activity. A. Reduction of MTT. B. IFN-γ production. The results are expressed as mean values 
± SD from two independent experiments with four to six animals per group. Significance at 
*p < 0.05 vs. controls (0 mg L-1 of warfarin) of the respective strain. 
On the other hand, the differential effects of warfarin on some hematological 
parameters and peripheral blood leukocytes in the two strains imply that the ef-
fect of warfarin might depend on the parameter/activity examined. Indeed, the 
differential sensitivity of individuals of these two strains to warfarin was demon-
strated by the hemoconcentration in AO rats (resulting from an increase in the 
number of red blood cells) following the consumption of the higher warfarin dose. 
A decrease in the lymphocyte counts in the peripheral blood of rats that had 
consumed warfarin accounted for a drop in the leukocyte counts in both rat strains. 
This could not be ascribed to warfarin cytotoxicity, as there was a lack of changes 
in the viability of freshly isolated mononuclear cells. The underlying mechanisms 
of leuko/lymphopenia are presently unknown, but leukocyte migration to the fo-
cuses of hemorrhage in peripheral tissues might be responsible. Increases in im-
mature bone marrow neutrophils imply that there is a need for these cells in the 
periphery and that this might be an underlying mechanism to uphold neutrophil 
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numbers in DA rats. Neutrophil attendance in lungs (pronounced in AO rats) im-
plies the exchange of neutrophils from circulation with the lung’s intravascular 
reservoir of leukocytes (marginated pool).31  
Differential effects of warfarin consumption on leukocyte functional activity 
were observed in these strains. While no effects on granulocyte viability were ob-
served in AO rats, an increase in the MTT reducing capacity by cells from war-
farin-treated DA rats was observed. As the MTT assay depends on mitochondrial 
activity in viable cells and is influenced by their metabolic activity, it actually 
reflects the overall functional state of granulocytes.29,35 A cytochemical assay 
for the respiratory burst, which is a measure of cellular capacity to reduce NBT 
via tetrazolium reducing respiratory burst phagocyte oxidase, is often employed 
as an in vitro measure of peripheral blood granulocyte activation.36,37 Similar 
levels of spontaneous NBT reduction by granulocytes between controls and rats 
that had consumed warfarin imply the lack of the capacity of this chemical to 
activate granulocytes. However, significantly higher NBT reduction provoked by 
PMA in the granulocytes from warfarin-treated DA rats compared to the controls 
indicated to a primed state of these cells, i.e., a state of increased responsiveness 
to exogenous stimulation.38 An increase in intracellular MPO content, which along 
with phagocyte oxidase, is a source of oxidant activity in phagocytes,39 empha-
sises the effect of warfarin intake on the oxidative activities of granulocyte in 
peripheral blood. The priming of granulocytes of DA rats for the respiratory burst 
and the higher intracellular MPO content imply the higher responsiveness of 
these rats to warfarin, compared to AO rats.  
The lack of an effect of warfarin intake on the peripheral blood mononuclear 
cell production of IFN-γ (the main mononuclear cell cytokine under conditions of 
systemic inflammation) in DA when compared to AO rats implies the differential 
susceptibility of these cells to warfarin. In addition, the lack of priming of mono-
nuclears from warfarin-treated AO rats (similar levels of IFN-γ production in res-
ponse to ConA stimulation) in contrast to the increased levels of cytokine pro-
duced in DA rats shows refractoriness of the mononuclear cells to exogenous 
stimulation. These data also suggest that not only peripheral blood neutrophils, 
but also mononuclear cells present targets for warfarin. The underlying mecha-
nisms responsible for differential granulocyte and mononuclear cell responsive-
ness to oral warfarin might be ascribed to differences in signaling pathways and/or 
sensitivity to chemical signals, such as pro-inflammatory cytokines, known to 
modulate leukocyte activities. These assumptions warrant future attention. 
CONCLUSIONS 
The present study has demonstrated strain-related differential responsiveness 
to oral warfarin intake in rats not only in terms of anticoagulation, but in certain 
hematological parameters and in inflammation–relevant peripheral blood gra-
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nulocyte and mononuclear cell activity as well. Recognition of differences in 
quantitative and qualitative effects of oral warfarin on processes other than he-
mostasis might be of relevance for those humans who are on warfarin therapy.  
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Варфарин (3-α-ацетонилбензил)-4–хидроксикумарин) је антагонист витамина К 
(ВК) који инхибира процесе зависне од овог витамина, укључујући коагулацију крви. 
Осим тога, он испољава и активности које не зависе од витамина К као што су анти-
туморска и имуномодулаторна активност. У овом раду је испитан ефекат субакутног (30 
дана) оралног уноса варфарина на хематолошке параметре и активност леукоцита 
периферне крви код два соја пацова Albino Oxford (AO) и Dark Agouti (DA) који се раз-
ликују у осетљивости на исте хемијске агенсе. Код јединки АО соја запажена је већа 
смртност након конзумирања дозе од 4 mg L–1 као и већа осетљивост на антикоагу-
лантно дејство варфарина при нижим дозама (2 mg L–1) које је праћено повећањем 
неких хематолошких параметара. Иако код јединки оба соја долази до повећања броја 
неутрофилних леукоцита периферне крви при дози од 2 mg L–1, промене у основним 
проинфламаторним активностима ових ћелија су запажене само код јединки DA соја. 
Промене у броју неутрофилних леукоцита у крви DA јединки су праћене повећањем 
броја гранулоцитних прекурсора у коштаној сржи, док присуство неутрофила у плућима 
АО јединки указује на размену ћелија између периферне крви и плућног интраваску-
ларног пула ћелија. Диференцијалне сојно–зависне промене у активности мононукле-
арних ћелија периферне крви су такође запажене. Разлике у ефекту орално унетог вар-
фарина могу да имају импликације за особе на оралној варфаринској терапији. 
(Примљено 14. новембра 2012, ревидирано 30. јануара 2013) 
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